NGM Biopharmaceuticals, Inc. (NGM) |
|
1.085 0.035 (3.33%)
|
09-27 11:23 |
|
Open: |
1.07 |
Pre. Close: |
1.05 |
|
High:
|
1.1 |
Low:
|
1.05 |
|
Volume:
|
56,014 |
Market Cap:
|
90(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:48:29 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.2  One year: 2.83 |
| Support: |
Support1: 1 Support2: 0.84 |
| Resistance: |
Resistance1: 1.88 Resistance2: 2.43 |
| Pivot: |
1.28 |
| Moving Average: |
MA(5): 1.07 MA(20): 1.43
MA(100): 2.56 MA(250): 4.22 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 6.8 %D(3): 5 |
| RSI: |
RSI(14): 21.6 |
| 52-week: |
High: 13.34 Low: 1 |
| Average Vol(K): |
3-Month: 308 (K) 10-Days: 337 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NGM ] has closed above bottom band by 23.1%. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.11 - 1.12 |
1.12 - 1.12 |
|
Low:
|
1.02 - 1.03 |
1.03 - 1.04 |
|
Close:
|
1.04 - 1.05 |
1.05 - 1.06 |
|
Company Description |
|
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 27 Sep 2023
Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential ... - PR Newswire
Tue, 26 Sep 2023
Geographic Atrophy Market Anticipates Impressive Growth ... - Digital Journal
Fri, 22 Sep 2023
NGM Biopharmaceuticals Inc (NGM) has fallen -12.21% in a Week, Should You Hold? - InvestorsObserver
Wed, 20 Sep 2023
Intrahepatic Cholangiocarcinoma Market to Grow Rapidly During the ... - Bloomberg
Wed, 20 Sep 2023
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2 ... - Nasdaq
Mon, 18 Sep 2023
Should You Buy NGM Biopharmaceuticals Inc (NGM) Stock on Monday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
83 (M) |
| Shares Float |
40 (M) |
|
% Held by Insiders
|
21.7 (%) |
|
% Held by Institutions
|
59.7 (%) |
|
Shares Short
|
2,520 (K) |
|
Shares Short P.Month
|
3,270 (K) |
Stock Financials |
|
EPS
|
-1.9 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.31 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-596 |
|
Return on Assets (ttm)
|
-39.8 |
|
Return on Equity (ttm)
|
-70.1 |
|
Qtrly Rev. Growth
|
-82.9 |
|
Gross Profit (p.s.)
|
-1.52 |
|
Sales Per Share
|
0.35 |
|
EBITDA (p.s.)
|
-2.12 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-141 (M) |
|
Levered Free Cash Flow
|
-79 (M) |
Stock Valuations |
|
PE Ratio
|
-0.57 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.46 |
|
Price to Sales
|
3 |
|
Price to Cash Flow
|
-0.64 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
